Is it justified to give antisecretory drugs before an endoscopy in case of symptoms suggestive of gastro-oesophageal reflux disease? Pro

被引:0
|
作者
Galmiche, JP [1 ]
Delbende, B [1 ]
Zerbib, E [1 ]
机构
[1] CHU Nantes, Dept Gastroenterol & Hepatol, Hotel Dieu, F-44035 Nantes, France
关键词
gastro-oesophageal reflux disease; endoscopy; empirical therapy; cost-effective strategy; therapeutic trial; proton pump inhibitors;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
引用
收藏
页码:438 / 444
页数:7
相关论文
共 29 条
  • [21] TRPV1 is a risk factor for sleep disturbance in patients with gastro-oesophageal reflux disease: a case control study
    Liu, Denong
    Xu, Lei
    Chen, Lei
    Hu, Jieqiong
    Wu, Danjuan
    Wang, Guanjun
    Shen, Haowei
    Zhang, Xiaoqin
    Ji, Yunxin
    Ruan, Liemin
    Lou, Zhongze
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2023, : 844 - 855
  • [22] A prospective study of gastro-oesophageal reflux disease symptoms and quality of life 1-year post-laparoscopic sleeve gastrectomy
    Robertson, Andrew G. N.
    Cameron, Andrew J.
    Joyce, Brian
    Le Page, Phil
    Tulloh, Bruce
    de Beaux, Andrew C.
    Lamb, Peter J.
    JOURNAL OF MINIMAL ACCESS SURGERY, 2019, 15 (03) : 229 - 233
  • [23] Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease
    Zerbib, F.
    des Varannes, S. Bruley
    Roman, S.
    Tutuian, R.
    Galmiche, J. -P.
    Mion, F.
    Tack, J.
    Malfertheiner, P.
    Keywood, C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (08) : 911 - 921
  • [24] Randomised clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal reflux disease who have persistent symptoms despite PPI therapy
    Shaheen, N. J.
    Adler, J.
    Dedrie, S.
    Johnson, D.
    Malfertheiner, P.
    Miner, P.
    Meulemans, A.
    Poole, L.
    Tack, J.
    Thielemans, L.
    Troy, S.
    Vakil, N.
    Zerbib, F.
    Ruth, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (07) : 649 - 661
  • [25] Omeprazole -: A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs
    Langtry, HD
    Wilde, MI
    DRUGS, 1998, 56 (03) : 447 - 486
  • [26] Guidelines for the diagnostic and therapeutic management of patients with gastro-oesophageal reflux disease - A position statement of the Italian Association of Hospital Gastroenterologists (AIGO), Italian Society of Gastrointestinal Endoscopy (SIED), and Italian Society of Gastroenterology (SIGE)
    Baldi, F
    Crotta, S
    Penagini, R
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 30 (01): : 107 - 112
  • [27] Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months
    Talley, NJ
    Venables, TL
    Green, JRB
    Armstrong, D
    O'Kane, KPJ
    Giaffer, M
    Bardhan, KD
    Carlsson, RGS
    Chen, S
    Hasselgren, GS
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2002, 14 (08) : 857 - 863
  • [28] Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice
    Venables, TL
    Newland, RD
    Patel, AC
    Hole, J
    Wilcock, C
    Turbitt, ML
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (10) : 965 - 973
  • [29] Long-term management of patients with symptoms of gastro-oesophageal reflux disease -: a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting
    Hansen, ÅN
    Bergheim, R
    Fagertun, H
    Lund, H
    Wiklund, I
    Moum, B
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (01) : 15 - 22